Table 2.
Shows the endpoints reported by each of the included trials
| Trials | No of patients (DAPT + TAPT) | Follow up period (month) | Reported endpoints/outcomes |
|---|---|---|---|
| Han 2009 [6] | 263 | 12 | MACEs, TVR, and ADR. |
| Lee 2011 [33] | 176 | 12 | MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR. |
| Lee 2008 [5] | 400 | 9 | MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR. |
| Lee 2007 [34] | 166 | 9 | MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR. |
| Yang 2011 [35] | 154 | – | PRU and PA |
| Yang 2007 [36] | 55 | 7 | PA |
| Capranzano 2012 [37] | 80 | 1 | PRU and PRI |
| Angiolillo 2008 [38] | 40 | 1 | PRI and PA |
| Angiolillo 2011 [39] | 106 | 1 | PRI |
| Ha 2013 [40] | 84 | 2 | PRU and PA |
Abbreviations: MACEs major adverse cardiac effects, TVR target vessel revascularization, TLR target lesion revascularization, BL bleeding, ST stent thrombosis, ADR adverse drug reactions, D death, MI myocardial infarction, PA platelet aggregation, PRI platelet reactivity index, PRU platelet reactivity unit